Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double‐blind, placebo‐controlled trial

Anzić, Srđan Ante; Turkalj, Mirjana; Župan, Ana; Labor, Marina; Plavec, Davor; Baudoin, Tomislav

doi:10.1111/coa.13005

Cited by 26 publications

(54 citation statements)

References 31 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proton pump inhibitors play a key role in management of suspected reflux‐associated CRS. Vaezi et al, in a DBRCT demonstrated a reduction in PND, SNOT‐20, and Quality of Life in Reflux and Dyspepsia scores in PND patients treated with lansoprazole 30 mg twice daily for 16 weeks vs placebo 679 . Median symptoms score improvement for patients treated with a PPI at 8 and 16 weeks was 55 and 50 respectively, relative to 3.5 and 5.0 for controls.…”

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 96%

“…Anzic et al performed a DBRCT where patients with diagnosed LPR and comorbid CRS received 8 weeks of omeprazole 20 mg twice daily. They found objective reductions in reflux symptom index and scores, improved symptoms of comorbid CRSsNP, and improved endoscopy scores 679 …”

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 97%

“…The exposure of nasopharyngeal and sinonasal mucosa to injurious gastric contents has been studied in adults 676–686 with gastroesophageal reflux disease (GERD) identified as a significant risk factor for poor outcomes following ESS 687 . Ulualp and Toohill identified a high rate of pharyngeal acid reflux and overall reflux events in adult CRS patients vs controls 688 .…”

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 99%

See 2 more Smart Citations

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

466

479

View full text Add to dashboard Cite

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.

show abstract

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 96%

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 97%

Section: Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)mentioning

confidence: 99%

See 1 more Smart Citation

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

466

479

View full text Add to dashboard Cite

show abstract

“…This may have led to overuse of proton pump inhibitors and increased medical cost. Although studies have shown that treatment of LPR symptoms also decreased nasal symptoms in chronic rhinosinusitis 19 and decreased nasal resistance on rhinomanometry, 20 proton pump inhibitors should not be initiated in all non-allergic rhinitis patients with a high reflux symptom index. Clinicians should treat moderate to severe nasal symptoms first.…”

Section: Discussionmentioning

confidence: 99%

The association between the reflux symptoms index and nasal symptoms among patients with non-allergic rhinitis

et al. 2021

View full text Add to dashboard Cite

Background Laryngopharyngeal reflux symptoms assessed with the reflux symptom index can overlap with non-allergic rhinitis symptoms. This study aims to explore the association between the reflux symptom index and nasal symptoms in non-allergic rhinitis patients. Methods A cross-sectional study was conducted on consecutive adults with non-allergic rhinitis. The reflux symptom index (score of more than 13 = laryngopharyngeal reflux) and nasal symptoms (categorised as mild (total score of 0–3), moderate (4–7) or severe (8–12)) were assessed. Results The study included 227 participants (aged 58.64 ± 12.39 years, 59.5 per cent female). The reflux symptom index scores increased with total nasal symptom scores (mild vs moderate vs severe, 8.61 ± 6.27 vs 12.94 ± 7.4 vs 16.40 ± 8.10; p < 0.01). Logistic regression indicated that laryngopharyngeal reflux is more likely in patients with severe nose block (odds ratio 5.47 (95 per cent confidence interval = 2.16–13.87); p < 0.01). Conclusion Laryngopharyngeal reflux symptoms are associated with nasal symptom severity, and nasal symptoms should be primarily treated. Those with predominant nose block and laryngopharyngeal reflux symptoms are more likely to have laryngopharyngeal reflux.

show abstract

“…It does seems that GERD could worsen the symptoms of bronchiectasis and a Korean group suggested that treatment with proton-pump inhibitors in bronchiectasis patients with a high body mass index could improve lung function [29]. However, the same association between GERD and worse respiratory symptoms can be found for asthma, CRS and COPD [30,31]. Although the association between GERD and all these chronic airway diseases is clear, a causal connection has not yet been established and further investigation considering potential confounding factors is surely needed.…”

Section: Introductionmentioning

confidence: 99%

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions

et al. 2018

View full text Add to dashboard Cite

Bronchiectasis is a clinical and radiological diagnosis associated with cough, sputum production and recurrent respiratory infections. The clinical presentation inevitably overlaps with other respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). In addition, 4-72% of patients with severe COPD are found to have radiological bronchiectasis on computed tomography, with similar frequencies (20-30%) now being reported in cohorts with severe or uncontrolled asthma. Co-diagnosis of bronchiectasis with another airway disease is associated with increased lung inflammation, frequent exacerbations, worse lung function and higher mortality. In addition, many patients with all three disorders have chronic rhinosinusitis and upper airway disease, resulting in a complex "mixed airway" phenotype.The management of asthma, bronchiectasis, COPD and upper airway diseases has traditionally been outlined in separate guidelines for each individual disorder. Recognition that the majority of patients have one or more overlapping pathologies requires that we re-evaluate how we treat airway disease. The concept of treatable traits promotes a holistic, pathophysiology-based approach to treatment rather than a syndromic approach and may be more appropriate for patients with overlapping features.Here, we review the current clinical definition, diagnosis, management and future directions for the overlap between bronchiectasis and other airway diseases.

show abstract

Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double‐blind, placebo‐controlled trial

Abstract: The results of our trial suggest that omeprazole 20 mg OD for 8 weeks was effective in reducing signs and symptoms of both LPR and CRS, although in most patients still present at the end of the trial.

Cited by 26 publications

References 31 publications

International consensus statement on allergy and rhinology: rhinosinusitis 2021

International consensus statement on allergy and rhinology: rhinosinusitis 2021

The association between the reflux symptoms index and nasal symptoms among patients with non-allergic rhinitis

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions

Contact Info

Product

Resources

About